Literature DB >> 10682677

Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours.

M B Parliament1, M J Allalunis-Turner, A J Franko, P L Olive, R Mandyam, C Santos, B Wolokoff.   

Abstract

We recently showed that severe hypoxia was not universally present adjacent to necrosis in human glioma xenografts and spheroids established from the M059K, M006, M006X, M006XLo and M010b cell lines. Using these glioma models, we wished to test whether oxygen serves as a regulator of cellular VEGF expression in situ. In situ hybridization (ISH) and immunohistochemistry (IHC) were used to detect vascular endothelial growth factor (VEGF) mRNA and protein expression in sections of glioma xenografts and spheroids in which hypoxic regions and regions with well-oxygenated necrosis were identified on contiguous sections by use of the hypoxia-specific marker, 3H-misonidazole. Independent validation of the presence of radiobiologically hypoxic cells in M006 xenografts was undertaken using the comet assay. Northern blotting analyses of monolayer cells demonstrated significant up-regulation of VEGF mRNA in the M006X line at oxygen concentrations of 6% and below. ISH analysis of VEGF mRNA showed unexpectedly strong staining for VEGF mRNA across the entire viable rim of M006X and M006XLo glioma spheroids. Similarly, in virtually all xenograft tumours of the M059K, M006 and M010b lines, VEGF ISH showed similar staining across all regions of healthy cells up to the border of necrosis. Only in one M006X tumour was there a suggestion of increased VEGF expression in cells adjacent to necrosis. IHC for VEGF showed good concordance with the ISH results. IHC analysis of the VEGF receptor flt-1 showed strong tumour cell staining in M006XLo glioma cells. In human glioma spheroids and xenograft tumours, regions of severe hypoxia do not correspond to areas of up-regulated VEGF expression; in fact, VEGF expression is quite uniform. Furthermore, this and our previous study demonstrate that levels of VEGF expression vary among sublines (M006, M006X and M006XLo) derived from a single human glioma specimen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10682677      PMCID: PMC2363312          DOI: 10.1054/bjoc.1999.0975

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  41 in total

1.  Characterization of the receptors for vascular endothelial growth factor.

Authors:  N Vaisman; D Gospodarowicz; G Neufeld
Journal:  J Biol Chem       Date:  1990-11-15       Impact factor: 5.157

2.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.

Authors:  B Berse; L F Brown; L Van de Water; H F Dvorak; D R Senger
Journal:  Mol Biol Cell       Date:  1992-02       Impact factor: 4.138

3.  Correlation of histopathological features and proliferative potential of gliomas.

Authors:  I M Germano; M Ito; K G Cho; T Hoshino; R L Davis; C B Wilson
Journal:  J Neurosurg       Date:  1989-05       Impact factor: 5.115

4.  Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin.

Authors:  M A Goldberg; T J Schneider
Journal:  J Biol Chem       Date:  1994-02-11       Impact factor: 5.157

5.  Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only.

Authors:  E Brogi; T Wu; A Namiki; J M Isner
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

6.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.

Authors:  D Shweiki; A Itin; D Soffer; E Keshet
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

7.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

Authors:  K H Plate; G Breier; H A Weich; W Risau
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

8.  Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells.

Authors:  M J Allalunis-Turner; R S Day; J D McKean; K C Petruk; P B Allen; K E Aronyk; B K Weir; D Huyser-Wierenga; D S Fulton; R C Urtasun
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

9.  Modulation of oxygen consumption rate and vascular endothelial growth factor mRNA expression in human malignant glioma cells by hypoxia.

Authors:  M J Allalunis-Turner; A J Franko; M B Parliament
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

10.  Ascorbate anion potentiates cytotoxicity of nitro-aromatic compounds under hypoxic and anoxic conditions.

Authors:  C J Koch; R L Howell; J E Biaglow
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640

View more
  17 in total

1.  Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment.

Authors:  Alisa Madalina Popescu; Oana Alexandru; Corina Brindusa; Stefana Oana Purcaru; Daniela Elise Tache; Ligia Gabriela Tataranu; Citto Taisescu; Anica Dricu
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

2.  Hypoxia and VEGF mRNA expression in human tumors.

Authors:  L S Ziemer; C J Koch; A Maity; D P Magarelli; A M Horan; S M Evans
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

3.  Suppression of matrix metalloproteinase activity by SI-27: detection by a new activity assay with S-2444, a specific chromogenic peptide.

Authors:  Daizo Yoshida; Kunihiro Watanabe; Masahiro Noha; Hiroshi Takahashi; Akira Teramoto
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

4.  Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.

Authors:  Alexander M Spence; Mark Muzi; Kristin R Swanson; Finbarr O'Sullivan; Jason K Rockhill; Joseph G Rajendran; Tom C H Adamsen; Jeanne M Link; Paul E Swanson; Kevin J Yagle; Robert C Rostomily; Daniel L Silbergeld; Kenneth A Krohn
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

5.  Hypoxic regulation of cytoglobin and neuroglobin expression in human normal and tumor tissues.

Authors:  Marwan Emara; A Robert Turner; Joan Allalunis-Turner
Journal:  Cancer Cell Int       Date:  2010-09-09       Impact factor: 5.722

Review 6.  Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.

Authors:  David A Reardon; Patrick Y Wen; Annick Desjardins; Tracy T Batchelor; James J Vredenburgh
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

7.  Expression and hypoxic up-regulation of neuroglobin in human glioblastoma cells.

Authors:  Marwan Emara; Nicole Salloum; Joan Allalunis-Turner
Journal:  Mol Oncol       Date:  2008-12-12       Impact factor: 6.603

8.  Drug-induced apoptosis by a matrix metalloproteinase inhibitor, SI-27 on human malignant glioma cell lines; in vitro study.

Authors:  Ryuzaburo Kanazawa; Daizo Yoshida; Hiroshi Takahashi; Yuichi Sugisaki; Satoru Suzuki; Akira Teramoto
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

Review 9.  The emerging role of anti-angiogenic therapy for malignant glioma.

Authors:  David A Reardon; Annick Desjardins; Jeremy N Rich; James J Vredenburgh
Journal:  Curr Treat Options Oncol       Date:  2008-02-07

Review 10.  Protein tyrosine phosphatases in glioma biology.

Authors:  Anna C Navis; Monique van den Eijnden; Jan T G Schepens; Rob Hooft van Huijsduijnen; Pieter Wesseling; Wiljan J A J Hendriks
Journal:  Acta Neuropathol       Date:  2009-11-21       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.